In English | En español

National Cancer Institute

at the National Institutes of Health

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI

Clinical Trials Search Results

Page Options

Email This Document

Clinical Trial Questions?
Get Help:
1-800-4-CANCER
LiveHelp online chat

Popular Resources

Help Using the NCI Clinical Trials Search Form
How to Find a Cancer Treatment Trial
Learn About Clinical Trials
About NCI's List of Cancer Clinical Trials
NCI Dictionary of Cancer Terms
NCI Drug Dictionary
Featured Clinical Trials Supported by NCI

View Content for:

Patients
Health Professionals

Display:

Title
Description with: Locations Eligibility
Full Trial Description
Custom

Results 1-25 of 182 for your search:

Cancer Type/Condition:  Skin cancer, melanoma
Stage/Subtype:  stage IV melanoma
Country:  U.S.A.
Trial Type:  Treatment
Trial Status:  Active

Hide Search Criteria

Show Search Criteria

Help with Results

Select All on Page Sort by: Show Results per Page

HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma

Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 12PLK01, NCT01683188

A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 11718, UVACC-ONYX-11718, UVACC-HIC-11860, EUDRACT-2005-0000941-12, BAYER-UVACC-ONYX-11718, NCT00111007

Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 10-154, NCT01223248

Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III or Stage IV Melanoma That Has Been Removed by Surgery

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-02649, E1609, CDR0000692568, U10CA021115, ECOG-E1609, NCT01274338

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 115306, NCT01584648

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 116513, NCT01597908

Melanoma Gamma Knife

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2011-0875, NCT01644591

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: GO28141, 2012-003008-11, NCT01689519

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA209-037, 2012-001828-35, NCT01721746

10.

Phase I/II Study of Sorafenib Tosylate, Bevacizumab, and Oxaliplatin in Patients with Metastatic Malignant Melanoma. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: POHA-0603, 06-03, NCT00538005

11.

Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: CDR0000573370, UMDNJ-0120070076, 0120070076, NCT00553683

12.

Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 2225.00, NCI-2010-00108, K12CA076930, FHCRC-2225.00, IR-6881, BMS-CA184-062, NCT00871481

13.

Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 200807728, NCT00925132

14.

A Phase I/II Study of TPI 287 - Temozolomide Combination in Melanoma

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 15 and over
Sponsor: Other
Protocol IDs: 2009-0357, NCT01067066

15.

IL15 Dendritic Cell Vaccine for Patients With Resected Stage III (A, B or C) or Stage IV Melanoma

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 21 to 75
Sponsor: NCI, Other
Protocol IDs: 009-273, R01CA140602, NCT01189383

16.

RO4929097 And Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-02533, MDA-2009-0582, U01CA062461, N01CM62202, CDR0000686136, 2009-0582, 8543, NCT01217411

17.

Treating Metastatic Cancer With Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 110013, 11-C-0013, NCT01218867

18.

Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 110011, 11-C-0011, NCT01236573

19.

A Clinical Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: BBI608-201, NCT01325441

20.

Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UPCC 01611, NCT01350401

21.

Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic Melanoma

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 110170, 11-C-0170, NCT01369888

22.

IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: 2011-0073, NCT01409174

23.

Safety Study of Adenovirus Vector Engineered to Express hIL-12 (Human Interleukin 12) in Combination With Activator Ligand to Treat Melanoma

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 60
Sponsor: Pharmaceutical / Industry
Protocol IDs: ADA1001, ATI001-101, NCT01397708

24.

E7050 in Combination With E7080 in Subjects With Advanced Solid Tumors (Dose Escalation) and in Subjects With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2)

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: not specified
Sponsor: Pharmaceutical / Industry
Protocol IDs: E7050-G000-901, NCT01433991

25.

RADVAX: A Stratified Phase I/II Dose Escalation Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Metastatic Melanoma

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UPCC 06611, NCT01497808

Select All on Page

Help with Results

We Can Answer Your Questions
1-800-4-CANCER
LiveHelp Online Chat

NCI Home
Contact Us
Policies
Accessibility
Viewing Files
FOIA
Site Help
Site Map